Transcatheter Heart Valve Procedures
Customize your policy alerts
Sign up for Blue Cross Blue Shield - North Carolina Policy SURG.00121 alerts
Get alerted when Policy SURG.00121 changes without checking for updates manually.
Monitor payer policy activity
Coverage policy for transcatheter (catheter-based) replacement and repair procedures of the aortic, mitral, tricuspid, and pulmonary heart valves for Blue Cross Blue Shield - North Carolina members.
FDA expanded indications in 2025 for Edwards SAPIEN 3 family valves to include treatment of asymptomatic severe native calcific aortic stenosis.
FDA expanded indication in August 2025 for Medtronic Evolut system to permit implantation of a new Evolut valve within a previously implanted transcatheter valve (Redo-TAVR) for high-risk individuals.
RCT evidence (Kapadia et al., 2022) did not show that use of the Sentinel cerebral embolic protection device reduced stroke within 72 hours after TAVR.
Coverage Criteria for Transcatheter Heart Valve Procedures
Transcatheter Aortic Valve Replacement (TAVR) — primary native valve
Covered when ALL of the following are met
Two-physician determination required.
Valve-in-valve TAVR (bioprosthetic surgical valve failure)
Covered when ALL of the following are met
Two-physician determination required.
Transcatheter mitral edge-to-edge repair — primary (degenerative) MR
Covered when ALL of the following are met
Two-physician/multidisciplinary team determination required.
Transcatheter mitral edge-to-edge repair — functional (secondary) MR
Covered when ALL of the following are met
Two-physician/multidisciplinary team determination required.
Transcatheter pulmonary valve implantation (TPV)
Covered when ALL of the following are met
Covered when trial/guideline-aligned criteria are met
Coverage considerations described in these chunks align with guideline and trial-based indications; covered when ALL of the following are met (per content):
From ACC/AHA guideline criteria and PARTNER enrollment definitions.
EARLY TAVR enrolled asymptomatic severe AS ≥65 in trial context; otherwise guidance focuses on symptomatic patients.
Documented surgeon agreement required in PARTNER B; STS thresholds referenced in FDA expansions and trial inclusion.
ESC/ACC guidance and trial protocols required assessment of access suitability.
Coverage considerations and selection criteria
Coverage and selection should follow multidisciplinary heart team assessment and device labeling; evidence-based indications and FDA approvals are referenced for specific device uses.
Consistent with major TAVR and mitral trials requiring multi-physician confirmation of eligibility.
Device labeling and trial evidence should be documented.
Evidence mainly from registries and observational studies; document device labeling and registry follow-up requirements.
TEER (Transcatheter edge-to-edge repair) coverage
Covered when ALL of the following are met
Based on ACC/AHA recommendations and COAPT/RESHAPE-HF2 trial inclusion criteria.
TEER for chronic primary MR
Covered when ALL of the following are met
Category 2a recommendation per ACC/AHA guideline and device labeling.
TMVR (Tendyne) coverage
Covered when ALL of the following are met
FDA approval May 23, 2025; evidence from feasibility studies and follow-up cohorts.
Mitral valve-in-valve (ViV) coverage
Covered when ALL of the following are met
FDA expanded approvals and combined TVT/P3 MViV analyses inform selection and registry follow-up requirements.
Evidence summaries relevant to coverage
Key evidence and regulatory findings informing clinical coverage:
FDA required manufacturer registry tracking as a condition of expanded approval.
Subjective quality‑of‑life improvements drove the composite outcome; interpretation requires caution.
Further study needed to assess mortality and hospitalization impact.
Ongoing longer-term follow-up planned.
Medically Necessary - general device and heart team criteria
Covered when ALL of the following are met
Supported by device indications and major trials requiring heart team assessment.
See device labeling and device-specific chunks for exact parameters.
As specified in device labeling and ACC/AHA guidance.
Medical Necessity and Investigational Designations
Coverage determinations in this document segment:
Supported by policy statements on coverage and coding.
See investigational listings and coding notes.
Policy statements (MN / INV / NMN) — referenced
Policy includes medically necessary (MN), investigational (INV), and not medically necessary (NMN) statements for various transcatheter valve procedures; document history records modifications to these statements.
Document history entries summarize revisions to MN/INV/NMN designations and coding updates.
Valve-in-valve TAVR implantation within a previously implanted transcatheter aortic valve ("Redo TAVR") is designated in this policy as investigational and not medically necessary for all indications.
Cerebral embolic protection devices used during TAVR (for example, the Sentinel™ Cerebral Protection System) are considered investigational and not medically necessary for all indications; randomized trial evidence has not demonstrated a consistent clinical benefit (no reduction in stroke within 72 hours) and registry data have not shown a clear outcome advantage.
Valve-in-valve transcatheter mitral valve replacement and transcatheter tricuspid valve repair or replacement are listed as investigational and not medically necessary for all indications in this policy, reflecting limited comparative randomized evidence and ongoing evaluation of these approaches.
Transcatheter mitral valve repair using percutaneous annuloplasty devices (for example, the CARILLON Mitral Contour System) and some transcatheter mitral valve replacement systems (for example, Tendyne at the time of earlier updates) are identified as investigational and not medically necessary when used outside established, FDA‑approved indications or when evidence is limited.
Some early TAVR trials excluded individuals with significant coronary artery disease or peripheral arterial disease; the document notes these exclusions limit generalizability of trial results to patients with those comorbidities.
The policy text does not list explicit procedural exclusions in the cited sections; however, it documents limitations including higher long‑term mortality reported in some valve‑in‑valve cohorts and uncertainty in comparative outcomes for certain ViV groups.
Randomized and registry evidence to date has not consistently demonstrated that implantation of cerebral embolic protection devices during TAVR provides added clinical benefit; a large RCT did not show reduced stroke at 72 hours and registry/meta‑analytic data have not shown consistent outcome improvements.
Procedures or devices that do not have FDA approval for the intended indication (for example, the CARILLON system for functional mitral regurgitation at the time of the policy update) or those supported only by limited, noncomparative evidence are considered investigational and not medically necessary until sufficient evidence or regulatory clearance is established.
There are currently no published randomized trials directly comparing transcatheter tricuspid valve replacement (TTVR) or transcatheter tricuspid TEER (T‑TEER) to open surgical repair/replacement as isolated procedures; surgical alternatives and the limited comparative evidence are discussed as context for investigational designations.
When the policy's clinical criteria are not met for the procedures and codes listed, services are considered Not Medically Necessary and may be denied.
Procedures explicitly labeled investigational in the Position Statement (for example, redo TAVR) and the cerebral embolic protection add‑on code CPT 33370 are excluded from coverage as investigational and not medically necessary when used for those indications.
Federal and State law, together with the member's contract language and specific contractual provisions, take precedence over this Medical Policy; the member's contract benefits in effect on the date of service must be used when determining coverage eligibility.
Federal and State law, and contract language including plan definitions and exclusions, take precedence over Medical Policy; providers must apply the member's contract benefits in effect on the date services are rendered.
The document contains investigational and not medically necessary statements addressing transcatheter mitral valve leaflet repair, percutaneous annuloplasty, and other novel transcatheter mitral procedures; such statements are intended to reflect current evidence limitations.
Transcatheter valve replacements (aortic, pulmonic, and valve‑in‑valve procedures) are not medically necessary when the specified coverage criteria in this policy are not met.
Transcatheter mitral edge‑to‑edge repair (TEER) is not medically necessary for treatment of primary or secondary MR when the policy's specified clinical criteria (including symptom class, anatomy, and GDMT requirements for secondary MR) are not met.
Early randomized trial results (for example, EARLY TAVR) are presented as trial evidence and do not by themselves establish routine coverage for asymptomatic severe aortic stenosis outside of FDA‑labeled indications or trial contexts.
Routine use of cerebral embolic protection devices during TAVR is not supported by randomized evidence demonstrating a reduction in stroke within 72 hours and therefore is not endorsed as standard practice in this policy.
Randomized trial data for the Sentinel Cerebral Protection System did not demonstrate a reduction in stroke or other clinical benefit in the first 72 hours after TAVR, supporting the policy's not‑medically‑necessary stance for routine use.
Use of transcatheter mitral procedures in clinical settings lacking sufficient comparative evidence (for example, certain TMVR devices or novel mitral systems outside approved indications) is described as investigational or not medically necessary pending stronger comparative data.
Evidence supporting mitral valve‑in‑valve (ViV) procedures is largely limited to uncontrolled cohorts, registries, and meta‑analyses; while FDA analyses of combined registry and study cohorts have shown encouraging short‑term outcomes, longer‑term data and prospective comparative trials are limited.
For the CPT and ICD‑10‑PCS procedure codes listed in the policy, services will be considered Not Medically Necessary when the specified clinical criteria or device indications in this policy are not met.
When listed procedure codes are submitted but the policy clinical criteria are not met, the services are Not Medically Necessary; procedures the Position Statement designates investigational (for example, redo TAVR) and CPT 33370 are specifically identified as investigational and not medically necessary.
Document history records additions of investigational/not medically necessary (INV/NMN) statements for mitral valve replacement and other transcatheter procedures over time; reviewers should consult the current policy text and revision history for the most recent position statements.
Multiple sections of the policy have historically declared certain transcatheter valve procedures or devices investigational or not medically necessary for specified indications; these INV/NMN statements are updated as device approvals and evidence evolve.
Procedure, Diagnosis, and Billing Codes
| No CPT codes listed in this section | The provided document text in these chunks does not list specific CPT/HCPCS/ICD-10 codes. |
| affected codes | Codes referenced in prior authorization guidance (document indicates affected codes but does not list specific CPT/HCPCS codes in this excerpt). |
| No codes listed |
| 33361 | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approach |
| 33362 | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach |
| 33363 | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach |
| 33364 | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach |
| 33365 | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transaortic approach (eg, median sternotomy, mediastinotomy) |
| 33366 | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transapical exposure (eg, left thoracotomy) |
| 33367 | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with percutaneous peripheral arterial and venous exposure (eg, left thoracotomy) |
| 33368 | TAVR with cardiopulmonary bypass support with open peripheral arterial and venous cannulation (eg, femoral, iliac, axillary vessels) [add-on] |
| 33369 | TAVR with cardiopulmonary bypass support with central arterial and venous cannulation (eg, aorta, right atrium, pulmonary artery) [add-on] |
| 33418 | Transcatheter mitral valve repair, percutaneous approach, including transseptal puncture when performed; initial prosthesis |
| 02RF3JH | Replacement of aortic valve with synthetic substitute, transapical, percutaneous approach |
| 02RF3JZ | Replacement of aortic valve with synthetic substitute, percutaneous approach |
| 02RF4JZ | Replacement of aortic valve with synthetic substitute, percutaneous endoscopic approach |
| 02RH3JH | Replacement of pulmonary valve with synthetic substitute, transapical, percutaneous approach |
| 02RH3JZ | Replacement of pulmonary valve with synthetic substitute, percutaneous approach |
| 02RH4JZ | Replacement of pulmonary valve with synthetic substitute, percutaneous endoscopic approach |
| 02UG3JZ | Supplement mitral valve with synthetic substitute, percutaneous approach |
| All diagnoses | All ICD-10 diagnosis codes |
| 33999 | Unlisted procedure, cardiac surgery [when specified as transcatheter replacement of tricuspid heart valve or redo TAVR] |
| 0345T | tricuspid heart valve or redo TAVR |
| 0483T | Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; percutaneous approach, including transseptal puncture, when performed |
| 0484T | Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; transthoracic exposure (eg, thoracotomy, transapical) |
| 0544T | Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transseptal puncture |
| 0545T | Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach |
| 0569T | Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis |
| 0570T | Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session |
| 0646T | Transcatheter tricuspid valve implantation (TTVI)/replacement with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed |
| 33370 | Transcatheter placement and subsequent removal of cerebral embolic protection device(s), including arterial access, catheterization, imaging, and radiological supervision and interpretation, percutaneous [add-on] |
| 02RG3JH | Replacement of mitral valve with synthetic substitute, transapical, percutaneous approach |
| 02RG3JZ | Replacement of mitral valve with synthetic substitute, percutaneous approach |
| 02RG4JZ | Replacement of mitral valve with synthetic substitute, percutaneous endoscopic approach |
| 02RJ4JZ | Replacement of tricuspid valve with synthetic substitute, percutaneous endoscopic approach |
| X2RJ3RA | Replacement of tricuspid valve with multi-plane flex technology bioprosthetic valve, percutaneous approach, new technology group 10 |
| All diagnoses | Policy states 'All diagnoses' under ICD-10 Diagnosis sections |
| 33370 | CPT code added effective 01/01/2022 (document notes) |
| 0646T | CPT code added 07/01/2021 (document notes) |
| 0569T | CPT code added 01/01/2020 (document notes) |
| 0570T | CPT code added 01/01/2020 (document notes) |
| 0544T | CPT code added 07/01/2019 (document notes) |
| 0545T | CPT code added 07/01/2019 (document notes) |
| 0483T | CPT code added 01/01/2018 (document notes) |
| 0484T | CPT code added 01/01/2018 (document notes) |
| X2RJ3RA | ICD-10-PCS code added 10/01/2024 (document notes) |
| 0256T | removed 12/31/2012 |
| 0257T | removed 12/31/2012 |
| 0258T | removed 12/31/2012 |
| 0259T | removed 12/31/2012 |
Required Provider Actions, Documentation, and Prior Authorization
Document required clinical/echo criteria and surgeon/heart‑team determination
Coverage requires documentation that the patient meets the clinical and echocardiographic criteria listed in the policy (e.g., severe AS hemodynamics, MR grades, TPV RVOT thresholds) and, when specified, a determination of surgical risk or inoperability by at least two physicians or a multidisciplinary heart valve team.
- Demonstrate severity using policy thresholds (e.g., AVA ≤1.0 cm2 or mean gradient ≥40 mm Hg or peak velocity ≥4.0 m/sec).
- When required, document two-physician or multidisciplinary heart team concurrence on inoperability/high surgical risk.
Obtain prior authorization verifying severe symptomatic AS and documented surgical risk/inoperability
Prior authorization should confirm symptomatic severe aortic stenosis by objective measures and include documented surgical risk or inoperability adjudication (including STS risk score or two‑physician agreement) and planned access route consistent with device labeling.
- Include severity measurements (AVA, mean gradient, or peak velocity) and NYHA symptom class.
- Provide STS predicted 30‑day surgical mortality and documentation of ≥2 physicians' determination when indicating inoperability or elevated risk.
Prior authorization must document expanded‑indication rationale and heart‑team review
Requests involving expanded device indications (for example, SAPIEN 3 for asymptomatic severe AS or Evolut Redo‑TAVR) must include documentation of heart‑team assessment and device‑specific FDA approval/labeling or trial support used to justify the indication.
- For asymptomatic SAPIEN 3 use, cite FDA expanded indication and multidisciplinary heart‑team suitability.
- For Redo‑TAVR, include supporting RESTORE/registry evidence and documentation that patient meets high‑risk criteria per label.
Use Medical Policy and verify member benefits before adjudication
Consider the Medical Policy language when adjudicating coverage and verify benefit/coverage per the member's contract; the policy should inform but not replace contract or legal determinations.
- Verify the member's contract benefits in effect on the date of service.
- Use Medical Policy to assess medical necessity but confirm plan coverage terms separately.
Require prior authorization confirming heart‑team review and FDA‑consistent indication for mitral procedures
Prior authorization for transcatheter mitral procedures must confirm multidisciplinary heart‑team review and that the indication aligns with FDA‑labeled criteria (e.g., MitraClip for selected secondary MR after GDMT; Tendyne when surgery/TEER unsuitable).
- Include evidence of GDMT optimization and echocardiographic anatomic assessment (TEE) when applicable.
- Document heart‑team determination that surgery or TEER is unsuitable when TMVR or mitral ViV is requested.
Verify member contract benefits and legal precedence on date of service
Determine eligibility using the member's contract benefits in effect on the date services are rendered; federal and state law and contract language take precedence over Medical Policy.
- Always verify plan-specific coverage and any contract exclusions applicable to the date of service.
- Do not substitute Medical Policy for contract or legal requirements.
Prior authorization implied for listed CPT codes—use exact codes
The CPT codes listed under 'When services may be Medically Necessary when criteria are met' imply prior authorization is required; submit authorization requests referencing those specific CPT codes.
- Listed CPT codes include 33361–33369, 33418–33419, and 33477 among others.
- Prior authorization should reference the exact CPT code(s) for the planned procedure.
Provide exact procedure CPT/HCPCS and ICD‑10‑PCS codes on authorization requests
Submit authorization requests using the exact procedure CPT/HCPCS and ICD‑10‑PCS codes listed in the policy; when specified, use unlisted cardiac procedure code 33999 for procedures the policy identifies as such.
- Use codes such as 33999 when the policy specifies unlisted cardiac procedure coding.
- Include the precise CPT/HCPCS or ICD‑10‑PCS code(s) for the performed transcatheter valve procedure.
Follow contract and legal precedence over Medical Policy
Medical Policy should be consulted to assess medical necessity, but federal/state law and the member's contract language and benefits take precedence and must be used to determine eligibility.
- If contract language or applicable law conflicts with policy, follow the contract/law.
- Verify member benefits for the date of service before approving coverage.
Verify current policy revisions and coding prior to authorization/claim submission
Check the policy for recent revisions and coding updates; verify current prior authorization requirements and code lists before submitting authorizations or claims.
- Document history records coding and MN/INV/NMN revisions—confirm applicable CPT and ICD‑10‑PCS codes.
- Recheck the policy for any updates to prior authorization or code requirements.
Confirm member benefit eligibility on date of service
Use the member's contract benefits in effect on the date services are rendered to determine eligibility; plan terms determine coverage even where Medical Policy provides criteria.
- Confirm member benefits on date of service.
- Do not assume policy criteria guarantee coverage without plan benefit verification.
Document maximally tolerated GDMT (two‑physician confirmation) before TEER for secondary MR
For functional (secondary) MR, document that MR severity persists despite maximally tolerated guideline‑directed medical therapy as determined by at least two physicians before TEER is authorized.
- Record details of GDMT and duration of optimization.
- Include multidisciplinary heart‑team confirmation that medical therapy was maximized and the patient remains symptomatic.
No other step‑therapy rules specified in this policy segment
No step‑therapy (prior authorization) sequencing rules beyond those stated (GDMT requirement for secondary MR) are described in these policy sections.
- Policy does not list additional step‑therapy requirements in the provided chunks.
Prioritize contract and legal requirements when determining coverage
When making coverage decisions, prioritize the member's contract benefits and applicable federal/state law; Medical Policy is intended to guide medical necessity determinations but does not override contract or legal requirements.
- If contract provisions differ from policy, follow the contract or law.
- Document benefit verification and any contractual limitations in the authorization file.
Submit AS severity measures, STS score, and surgeon/heart‑team concurrence with authorization
Include clinical documentation of AS severity (AVA, mean gradient, or peak velocity), the STS risk score, and when applicable, concurrence of at least two surgeons or a multidisciplinary heart team when requesting authorization for TAVR or ViV procedures.
- Provide objective hemodynamic measurements per policy thresholds (e.g., AVA ≤1.0 cm2, mean gradient ≥40 mm Hg, peak velocity ≥4.0 m/sec).
- Include STS score and documentation of two‑physician agreement for inoperability/high surgical risk.
Include multidisciplinary heart‑team evaluation documentation in the record
Documentation for authorization should reflect multidisciplinary team assessment (including cardiology and cardiac surgery and other subspecialists as needed) confirming eligibility and planned approach.
- Record attendees and their determinations in the heart‑team note.
- Include imaging review and rationale for chosen access route.
Document heart‑team suitability determination and exhaustion/optimization of alternatives
Documentation must include heart‑team determination of suitability and evidence that alternative therapies were optimized or exhausted (for example, GDMT for secondary MR) when such requirements apply.
- For TMVR/ViV requests, document that surgery or TEER is unsuitable per heart‑team assessment.
- For secondary MR, document GDMT optimization and persistent symptoms.
Ensure FDA registry tracking requirements and selection criteria are met for mitral ViV
For Edwards Lifesciences mitral ViV expanded approval, the FDA requires manufacturer registry tracking; include evidence of registry enrollment or that the procedure meets the FDA‑approved cohort conditions when applicable.
- FDA required 3‑year registry tracking for intermediate‑risk mitral ViV patients or until enrollment goals are met.
- Ensure documentation supports that patient selection aligns with FDA cohort criteria.
Provide exact procedure and diagnosis codes; use unlisted code 33999 when specified
When requesting authorization or submitting claims, provide the exact CPT/HCPCS and ICD‑10‑PCS procedure codes listed in the policy; the policy also specifies use of unlisted code 33999 where applicable.
Use member's contract benefits on the date of service to determine eligibility
Use the member's contract benefits in effect on the date of service to determine eligibility; policy language does not supersede contract provisions.
- Verify benefit limitations, prior‑authorization requirements, and exclusions on the DOS.
- Document benefit verification results in the authorization record.
Check policy history and coding updates when validating authorizations and claims
Review document history and coding updates before processing requests—policy history documents additions and removals of MN/INV/NMN statements and CPT/ICD‑10‑PCS code changes.
Risk of denial if policy criteria are not met—provide complete supporting documentation
Services will be denied (Not Medically Necessary) when the policy's coverage criteria are not met; submit complete supporting documentation to avoid denial.
- If objective criteria (hemodynamics, symptom class, heart‑team determination) are missing or not met, the service is Not Medically Necessary.
- Ensure submitted records directly address each required criterion to reduce denial risk.
Denial risk if trial‑aligned severity thresholds or inoperability assessments are not documented
Failure to document trial‑aligned severity thresholds or a surgical inoperability/high‑risk assessment (including STS score and two‑physician concurrence where required) may lead to denial of TAVR/ViV requests.
- Document STS score and the surgeons' concurrence when claiming inoperability per PARTNER/registry definitions.
- Provide the objective severe AS measurements as defined by the policy.
Denial risk if multidisciplinary heart‑team evaluation is not documented
Lack of documentation of a multidisciplinary heart‑team evaluation when required may result in denial of coverage for TAVR or other transcatheter valve procedures.
- Include a heart‑team note listing participants and their recommendations.
- Document why the heart‑team favored the transcatheter approach over surgery.
Precedence of law/contract—risk of incorrect determinations if not applied
Federal and state law and contract language take precedence over Medical Policy; failure to apply contract or legal requirements may lead to incorrect coverage determinations.
- Always confirm applicable legal or contractual exclusions prior to authorization.
- Document reliance on contract provisions or legal requirements when they affect coverage.
Denial risk for TEER if heart‑team assessment or GDMT optimization is not documented
For secondary MR, absence of a documented multidisciplinary heart‑team assessment or lack of documented GDMT optimization may trigger denial for TEER requests.
- Provide heart‑team confirmation that GDMT was optimized and MR persisted.
- Include echocardiographic anatomy and LVEF/LVESD parameters supporting TEER candidacy.
Services billed with listed codes may be denied if policy criteria are unmet
When policy criteria are not met, services billed with the listed procedure codes will be considered Not Medically Necessary and may be denied.
- Denial applies to listed CPT/ICD‑10‑PCS codes when the required clinical criteria are lacking.
- Ensure clinical documentation directly supports each listed code's medical necessity.
CPT 33370 is investigational and may be denied if submitted
CPT code 33370 (placement and removal of cerebral embolic protection devices) is designated investigational and Not Medically Necessary and may be denied if billed.
- Do not expect coverage for CPT 33370 absent a contract exception; document any device‑specific rationale but anticipate denial.
- If submitted, clearly indicate investigational rationale and review contract language for exceptions.
Verify contract and legal precedence before approving procedures
Federal and state law and contract provisions take precedence over this Medical Policy; verify contractual and legal rules first when making coverage decisions or processing authorizations.
- Confirm whether statutory or plan language affects coverage for specific devices or procedures.
- Document application of contract or legal precedence in the authorization record.
Denial risk: listed procedure codes considered Not Medically Necessary without meeting criteria
Services for the listed procedure codes are Not Medically Necessary when the policy criteria are not met; submit documentation addressing each criterion to reduce denial likelihood.
- If any required clinical criterion is absent, the claim/authorization is at risk for denial.
- Address device‑specific and patient‑specific criteria in the request to support medical necessity.
Denial risk for billed services when policy criteria are unmet
Services billed with the listed codes will be denied when the policy's criteria are not met; ensure complete alignment of documentation with policy thresholds and heart‑team findings.
- Cross‑check submitted documentation against the policy's numeric thresholds and structural/anatomic requirements.
- Include heart‑team notes and objective measurements to substantiate coverage.
Apply legal and contract precedence to avoid inappropriate adjudications
Federal and State law and the member's contract benefits take precedence; failure to consider these may result in inappropriate coverage approvals or denials.
- Always verify and record the member's contract benefits and any applicable legal constraints.
- If conflicts arise between policy and contract/law, follow contract/law and document rationale.
Confirm contractual/legal exclusions before finalizing coverage decisions
Federal and State law and contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy; check these first to avoid incorrect denials or approvals.
- Document any contract‑based exclusions that affect coverage for specified procedures or devices.
- When in doubt, consult legal or contract administration before finalizing coverage decisions.
Document contractual/legal precedence when it changes coverage outcomes
Federal and State law and contract language take precedence over Medical Policy; ensure these are applied and documented when determining eligibility for coverage.
- Record specific contract clauses or laws relied upon when denying or approving services.
- Do not substitute policy for mandatory contract or legal provisions.
Verify and document legal/contract constraints before authorization
Federal and State law and contract language take precedence over Medical Policy; verify and document applicable legal or contractual constraints prior to authorization.
- If a plan excludes investigational procedures, document the exclusion and basis in the authorization record.
- Document application of statutory or regulatory requirements that affect coverage.
Background and Evidence Summary
Background: Transcatheter approaches provide catheter‑based alternatives to open surgical valve procedures for the aortic, mitral, pulmonary, and tricuspid valves; indications and device labeling have expanded over time from inoperable/high‑risk patients to selected lower‑risk populations as evidence, device technology, and regulatory approvals have evolved.
Evidence summaries: Key randomized trials, registries, and FDA device reviews (including PARTNER, SURTAVI, EVOLUT/CoreValve, NOTION, EARLY TAVR, TRILUMINATE, TRISCEND II, and TVT registry analyses) and related regulatory findings inform the policy's clinical coverage positions and device‑specific indications.
Routine use of cerebral embolic protection devices during TAVR is not supported by randomized evidence demonstrating a clinical benefit in reducing stroke at 72 hours; a large randomized trial failed to show a significant reduction in early stroke and registry data have not consistently demonstrated benefit.
Definitions and Abbreviations
References, Regulatory Summaries, and Revision History
Randomized trial evidence on the Sentinel device (Kapadia et al., n≈3,000) did not show a significant reduction in stroke within 72 hours after TAVR and therefore did not demonstrate a clinical benefit for routine use in that time frame.
Key trials and regulatory references informing policy include major randomized studies (PARTNER series, SURTAVI, EVOLUT/CoreValve, NOTION, EARLY TAVR) and FDA summaries/PMA and 510(k) device reviews that underpin device‑specific indications and approvals.
The policy cites numerous FDA premarket approval and 510(k) summaries and other authoritative sources to support device‑specific descriptions, labeling, and indications.
Policy published (document header shows Publish Date).
Last clinical review of the policy documented (Last review 2025-11-06).
Document notes FDA expanded indication in August 2025 for Medtronic Evolut system to permit Redo‑TAVR in high‑risk individuals (referenced in coverage/selection criteria).
Document records FDA expanded indications in 2025 for Edwards SAPIEN 3 family valves to include treatment of asymptomatic severe native calcific aortic stenosis based on EARLY TAVR evidence; reflected in coverage considerations.
Coding section updated to reflect 01/01/2022 CPT changes (document history lists coding updates over time).
Policy reviewed (11/07/2019) with updates to rationale, background, references and websites as recorded in document history.
Historic revision added MN statement for ViV TAVR and other updates to MN criteria (document history entries from 2016 noted).
Document metadata: the policy's revision history, publish date, and review dates are recorded in the document header and history sections for cross‑checking and version control.
The policy references an extensive peer‑reviewed literature list to support clinical statements; bibliography entries and citation lists are included in the document's reference sections.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.